(Sharecast News) - Microsaic announced the addition of a new technology capability to its platform on Friday, as part of its transition from equipment-only sales to remote detection and analysis of human diagnostics and environmental health monitoring.
The AIM-traded firm said the latest addition to the platform was expected to launch in the first half of 2022.

It said mass spectrometry (MS) was often considered the "gold standard" analytical technique for laboratory-based diagnosis.

Microsaic's compact technology allowed for MS analysis at point-of-need, providing a "unique capability" to detect a large range of chemical entities in human diagnostics and environmental monitoring.

The company said the addition to its platform was the integration of its compact MS technology with gas chromatography (GC), extending its existing applications in liquid chromatography (LC).

It explained that the combination would provide an "extensive range" of analysis required by end-users for chemical detection, for use in a combined market estimated to be worth more than $1bn.

"Our enhanced platform will provide us with a significant opportunity for screening in both human health and environmental applications," said chief executive officer Glenn Tracey.

"This transition to a data-centric and commercially focused company, strategically positions us at the core of addressing many global societal problems.

"Together, these advanced technologies and partnerships in human and environmental health, established this year are expected to completely transform our business in 2022."

At 1418 GMT, shares in Microsaic Systems were up 2.34% at 0.18p.